Publications

Show Filters

Searches all publications.

Search Fulltext

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-09-21
    E.g., 2018-09-21

Articles

Pages

79552 items
1:31 PM, Sep 14, 2018  |  BC Week In Review | Company News  |  Other News

Acorda loses Amprya appeal, reports Inbrija PDUFA delay

Acorda Therapeutics Inc. (NASDAQ:ACOR) fell $10.30 (37%) to $17.25 the week of Sept. 10 following setbacks related to multiple sclerosis drug Ampyra dalfampridine and Parkinson's disease candidate Inbrija levodopa inhalation powder (CVT-301). On Sept. 10,...
1:01 PM, Sep 14, 2018  |  BC Week In Review | Company News  |  Deals

Fate gets license to Gladstone's stem cell tech

Fate Therapeutics Inc. (NASDAQ:FATE) obtained an exclusive license to IP from the Gladstone Institutes covering the generation of induced pluripotent stem cells (iPS cells) using CRISPR-mediated gene activation. Gladstone will receive $100,000 up front and...
12:49 PM, Sep 14, 2018  |  BC Week In Review | Company News  |  Other News

Telo, GSK targeting TERT to halt glioblastoma cell immortality

Telo Therapeutics Inc. (San Francisco, Calif.) is exploiting a partnership with GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) to discover small molecules against an isoform of GABPB1, first identified as a cancer immortality target in a paper published...
12:16 PM, Sep 14, 2018  |  BC Week In Review | Company News  |  Sales & Marketing

MS Society protests NICE rejection of Ocrevus for primary progressive MS

The U.K.'s NICE issued a final appraisal determination (FAD) on Sept. 10 recommending against the use of Ocrevus ocrelizumab from Roche (SIX:ROG; OTCQX:RHHBY) to treat primary progressive multiple sclerosis with imaging features characteristic of inflammatory...
12:15 PM, Sep 14, 2018  |  BC Week In Review | Company News  |  Deals

Oncolytics to conduct pilot study of oncolytic virus with SOLTI

Oncolytics Biotech Inc. (TSX:ONC; NASDAQ:ONCY) partnered with the non-profit group SOLTI (Barcelona, Spain) to conduct a pilot study of the biotech's Reolysin pelareorep in the neoadjuvant setting for breast cancer. SOLTI will facilitate the trial,...
10:28 AM, Sep 14, 2018  |  BC Week In Review | Company News  |  Sales & Marketing

ICER finds opioid use disorder treatments not cost-effective

In a draft evidence report, ICER found that newer extended-release formulations of medication-assisted treatments (MATs) for opioid use disorder were not cost-effective compared with generic medicines. The institute compared the clinical effectiveness and value of three...
10:27 AM, Sep 14, 2018  |  BC Week In Review | Company News  |  Other News

Takeda to move U.S. headquarters to Boston area

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) will move its U.S. headquarters from Deerfield, Ill., to a to-be-determined site in the greater Boston area after its planned acquisition of Shire plc (LSE:SHP; NASDAQ:SHPG) closes next half. Takeda spokesperson...
10:27 AM, Sep 14, 2018  |  BC Week In Review | Company News  |  Deals

Boehringer to acquire oncolytic virus company ViraTherapeutics

Boehringer Ingelheim GmbH (Ingelheim, Germany) exercised an option to acquire oncolytic virus company ViraTherapeutics GmbH (Innsbruck, Austria). Boehringer gained the option under a 2016 deal to jointly develop ViraTherapeutics' oncolytic virus therapy platform and its...
10:27 AM, Sep 14, 2018  |  BC Week In Review | Company News  |  Deals

Zai Lab gets Chinese rights to Novocure's oncology tech

Novocure Ltd. (NASDAQ:NVCR) granted Zai Lab Ltd. (NASDAQ:ZLAB) exclusive rights to oncology platform Tumor Treating Fields in China, including Hong Kong and Macau, and Taiwan. Novocure will receive $15 million up front and is eligible for...
10:26 AM, Sep 14, 2018  |  BC Week In Review | Company News  |  Other News

Patient groups urge CVS to reconsider ICER-restricted formulary

At least 94 patient groups and individuals signed a letter urging CVS Health Corp. (NYSE:CVS) President and CEO Larry Merlo to reconsider a new formulary that would be restricted to drugs deemed cost effective by...

Pages